Donafenib
A kinase inhibitor used in cancer treatment
| Donafenib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Donafenib is an oral multikinase inhibitor used in the treatment of certain types of cancer. It is a derivative of sorafenib, designed to improve efficacy and reduce side effects. Donafenib is primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer.
Mechanism of Action
Donafenib works by inhibiting multiple tyrosine kinases, which are enzymes involved in the signaling pathways that regulate cell division and survival. By blocking these pathways, donafenib can slow down or stop the growth of cancer cells. It targets several kinases, including VEGFR, PDGFR, and RAF kinases, which are involved in tumor growth and angiogenesis.
Clinical Use
Donafenib is primarily indicated for the treatment of advanced hepatocellular carcinoma. It is used in patients who have not responded to other treatments or who are not candidates for surgical resection or liver transplantation. The drug is administered orally, and the dosage is adjusted based on the patient's response and tolerance.
Side Effects
Common side effects of donafenib include fatigue, diarrhea, hand-foot skin reaction, hypertension, and rash. More severe side effects can include liver dysfunction, bleeding, and cardiac issues. Patients are monitored regularly to manage these side effects and adjust treatment as necessary.
Development and Approval
Donafenib was developed as a modification of sorafenib, with the aim of improving its pharmacokinetic properties and reducing adverse effects. It has undergone clinical trials to establish its efficacy and safety profile. The drug has been approved for use in China for the treatment of hepatocellular carcinoma.
Comparison with Sorafenib
Donafenib and sorafenib share a similar mechanism of action, but donafenib has been shown to have a different side effect profile and may offer improved tolerability. Studies have compared the two drugs in terms of efficacy and safety, with some suggesting that donafenib may provide a better quality of life for patients due to fewer adverse effects.
Related pages
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
